mp.weixin.qq.com·· 4 hours agoPickScore95
PD-1/VEGF Bispecific Ivonescimab Plus Chemotherapy Meets Overall Survival Primary Endpoint in Phase 3 HARMONi-GI1 Biliary Tract Cancer Trial
In brief
Phase 3 HARMONi-GI1 data presented at the 2026 ESMO Congress show that ivonescimab combined with chemotherapy met the overall survival primary endpoint as first-line treatment for advanced biliary tract cancer. The regimen was compared head-to-head against durvalumab plus chemotherapy.
Why it matters
Head-to-head data comparing ivonescimab plus chemotherapy with durvalumab plus chemotherapy, reporting OS, PFS, ORR and bleeding risk together.
Source: mp.weixin.qq.com · mp.weixin.qq.com